Debt-to-equity of Aurinia Pharmaceuticals Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aurinia Pharmaceuticals Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • Aurinia Pharmaceuticals Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 46%, a 5.8% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Aurinia Pharmaceuticals Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 46% +2.5% +5.8% 30 Sep 2025
Q2 2025 45% +1.8% +4.1% 30 Jun 2025
Q1 2025 44% +1.3% +3% 31 Mar 2025
Q4 2024 44% +8.2% +23% 31 Dec 2024
Q3 2024 43% +15% +54% 30 Sep 2024
Q2 2024 43% +22% +101% 30 Jun 2024
Q1 2024 43% +27% +179% 31 Mar 2024
Q4 2023 36% +21% +144% 31 Dec 2023
Q3 2023 28% +14% +104% 30 Sep 2023
Q2 2023 22% +6.8% +46% 30 Jun 2023
Q1 2023 15% -0.12% -0.78% 31 Mar 2023
Q4 2022 15% -0.79% -5.1% 31 Dec 2022
Q3 2022 14% -1.6% -11% 30 Sep 2022
Q2 2022 15% 30 Jun 2022
Q1 2022 15% 31 Mar 2022
Q4 2021 15% 31 Dec 2021
Q3 2021 16% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.